Related Experiment Video
Updated: Aug 4, 2025

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
Published on: March 30, 2014
HIV and hypertension epidemiology
Ileana De Anda-Duran1, Alexander D Kimbrough1, Lydia A Bazzano1,2
1Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine.
Insights
Hypertension in people living with HIV (PLWH) is complex, influenced by HIV and its treatments. Management aligns with general guidelines but requires careful consideration of antiretroviral therapy drug interactions.
Area of Science:
- Cardiovascular Health
- Infectious Diseases
- Public Health
Background:
- Growing prevalence of HIV as a chronic condition.
- Increasing incidence of hypertension in the general population.
- The critical intersection of HIV and hypertension management.
Approach:
- Review of current literature on hypertension burden in people living with HIV (PLWH).
- Analysis of the complex pathogenesis linking HIV, inflammation, antiretroviral therapy (ART), and comorbidities.
- Evaluation of existing and emerging treatment recommendations.
Key Points:
- HIV contributes to hypertension through chronic inflammation, ART, and comorbidities like renal disease and insulin resistance.
- Standard non-pharmacological interventions (lifestyle changes) are recommended.
- Pharmacological treatment is similar to HIV-uninfected individuals, with careful attention to ART drug interactions.
Conclusions:
- Understanding the multifaceted pathogenesis of hypertension in PLWH is crucial for tailored clinical management.
- Further research is essential to elucidate hypertension's pathways and effects in the context of HIV.
- Integrated management strategies are needed for optimal cardiovascular health in PLWH.
Purpose Of Review:
The aim of this study was to provide an overview of the burden, pathogenesis, and recent recommendations for treating hypertension among people living with HIV (PLWH). This review is relevant because of the increase in the prevalence of HIV as a chronic disease and the intersection of the increasing prevalence of hypertension.
Recent Findings:
The contribution of HIV to the pathogenesis of hypertension is complex and still incompletely understood. Evidence suggests that chronic inflammation from HIV, antiretroviral treatment (ART), and comorbidities such as renal disease and insulin resistance contribute to developing hypertension in PLWH. Treatment is not distinct from guidelines for HIV-noninfected people. Nonpharmacological guidelines such as decreasing blood pressure by promoting a healthy lifestyle emphasizing exercise, weight loss, and smoking cessation are still recommended in the literature. The pharmacological management of hypertension in PLWH is similar, but special attention must be given to specific drugs with potential interaction with ART regimens. Further research is needed to investigate the pathways and effects of hypertension on HIV.
Summary:
There are different pathways to the pathogenesis of hypertension in PLWH. Clinicians should take it into consideration to provide more precise management of hypertension in PLWH. Further research into the subject is still required.
More Related Videos
Related Concept Videos
Hypertension II: Pathophysiology
Hypertension III: Clinical Manifestations and Diagnostic Studies
Hypertension I: Introduction
Sexually Transmitted Infections
Hypertension and Regulation of Blood Pressure
Retrovirus Life Cycles

